Evommune Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	13	7	5
Revenue Growth (YoY)	160.00%	40.00%	-
Gross Profit	13	7	5
Selling, General & Admin	14.34	12.77	10.85
Research & Development	71.47	64.24	32
Operating Expenses	85.81	77.01	42.85
Operating Income	-72.81	-70.01	-37.85
Interest Expense	-0.01	-0.03	-0.06
Interest & Investment Income	2.61	3.24	3.86
Other Non Operating Income (Expenses)	8.89	-0	-0
Pretax Income	-61.32	-66.81	-34.05
Net Income	-61.32	-66.81	-34.05
Preferred Dividends & Other Adjustments	1.5	1.5	-
Net Income to Common	-62.82	-68.31	-34.05
Shares Outstanding (Basic)	2	2	1
Shares Outstanding (Diluted)	2	2	1
Shares Change (YoY)	22.66%	20.35%	-
EPS (Basic)	-40.87	-45.29	-27.17
EPS (Diluted)	-40.87	-45.29	-27.17
Free Cash Flow	-78.39	-58.28	-30.09
Free Cash Flow Per Share	-50.99	-38.64	-24.01
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-560.07%	-1000.19%	-757.00%
Profit Margin	-483.25%	-975.83%	-681.06%
Free Cash Flow Margin	-602.96%	-832.61%	-601.76%
EBITDA	-71.39	-68.73	-36.85
D&A For EBITDA	1.42	1.29	1
EBIT	-72.81	-70.01	-37.85
Revenue as Reported	7	7	5

Updated Oct 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q